Cardiovascular Oncology: Exploring the Effects of Immune Checkpoint Inhibitors on Experimental Atherosclerosis

K. Poels¹, T.T.P. Seijkens¹, P.J.H. Kusters¹, M.E. Reiche¹, S.M. Den Toom¹, L. Beckers¹, M.P.J. de Winther¹, E. Lutgens¹
k.poels@amc.uva.nl ¹. Department of Medical Biochemistry, Amsterdam UMC - location AMC, Amsterdam, the Netherlands

Goal: study the effect of combined α CTLA4 and α PD1 antibodies on experimental atherosclerosis

Figure 1: ICI trigger an activated T cell profile, which accumulate in organs. Systemic inflammation was evident in ICI mice.

Figure 2: In the aortic arch, ICI treatment resulted in a hyper-inflammatory plaque phenotype that drives the progress of atherosclerosis. IX: intimal xanthoma, PIT: pathological intimal thickening, FCA: fibrous cap atheroma